Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Esperion rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Esperion Therapeutics's Return On Capital Employed Insights

Esperion Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but Esperion Therapeutics still reported an overall loss of $56.73 million.

Esperion Therapeutics: Q1 Earnings Insights

Esperion Therapeutics: Q1 Earnings Insights

Esperion Therapeutics (NASDAQ:ESPR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Esperion Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Esperion Therapeutics (NASDAQ:ESPR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Esperion Therapeutics (ESPR) Conference Call Follow this link to access the live webcast.

Organisations

Uber Technologies

CF Industries Holdings

Reinsurance Group

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play